Highlights from the American College of Rheumatology Conference
Introduction:
The American College of Rheumatology’s annual meeting, held from November 10th to 15th in San Diego, showcased groundbreaking research in rheumatology. Although I was not present, I am proud that my contributions at Novartis played a key role in some of the significant research presented.
Presented Work:
- Systemic Lupus Erythematosus Treatment:
Ianalumab has shown promise in a Phase 2 trial, significantly reducing B cell counts and autoantibody levels in Systemic Lupus Erythematosus (SLE) patients. The clinical responses were effective irrespective of the initial interferon gene signature status. Read abstract here - Sjoegren’s Disease Research:
In Sjögren’s Disease, Ianalumab demonstrated dose-dependent effects. The highest dose (300 mg) significantly modulated serum proteins and autoantibodies, aligning with the clinical efficacy observed in a Phase 2b trial. Read abstract here
Significance of Findings:
These studies mark significant advancements in the treatment of SLE and Sjögren’s Disease (SjD).
Conclusion:
The American College of Rheumatology Conference was a seminal event in rheumatology. I am proud to be part of Novartis, a company at the forefront of reimagining medicine for patient care.
Acknowledgments:
I extend my heartfelt thanks to the team who represented our work at the conference, showcasing our dedication and collective efforts in rheumatology research.
Disclaimer:
This blog post is intended for informational purposes only and should not be considered as medical advice. Always consult with a healthcare professional for medical advice and treatment options.
Author Notes:
In this post, I’ve provided a brief overview of the research I’ve been a part of at Novartis Biomedical Research. The information shared is derived from scientific studies that are publicly accessible and have been published in reputable journals. I welcome any feedback or comments you may have. For further inquiries or to get in touch, please visit my personal page.
